BridgeBio Pharma
BBIO
BBIO
197 hedge funds and large institutions have $2.58B invested in BridgeBio Pharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 58 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
8% less funds holding
Funds holding: 213 → 197 (-16)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
34% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 44
Holders
197
Holding in Top 10
7
Calls
$120M
Puts
$93.5M
Top Buyers
| 1 | +$33.1M | |
| 2 | +$21.3M | |
| 3 | +$18.8M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$14.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$10.9M |
Top Sellers
| 1 | -$29.7M | |
| 2 | -$18M | |
| 3 | -$16.9M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.6M |
| 5 |
Renaissance Technologies
New York
|
-$12.7M |